The Unmet Needs and Emerging Data in Patients with High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) competitive grant program seeks to support independent medical education (IME) activities that increase awareness of emerging data addressing the unmet needs in NMIBC.
Donor Name: Pfizer
State: All States
County: All Counties
Type of Grant: Grant
Deadline: 10/01/2025
Size of the Grant: $100,000 to $500,000
Grant Duration: 2 Years
Details:
Project Types and Area of Interest
- High risk non-muscle invasive bladder cancer (HR-NMIBC) is a heterogeneous disease associated with increased rates of recurrence and progression. While new treatment options are available for patients who develop BCG-unresponsive disease, there is a need for more effective treatment options for BCG-naive disease. While BCG is an effective treatment option that has been used for decades, up to 50% of high risk patients will develop disease recurrence or progression. When disease recurs or progresses, additional invasive treatments are often utilized, including repeat cytoscopy, TURBT, and potentially radical cystectomy. These procedures are often associated with additional morbidity and mortality.
- As more immunotherapy options enter the NMIBC treatment landscape, collaboration and coordination of care between urology and medical oncology is essential. Decisions on whether certain patients should undergo repeat treatments, like TURBT, versus employ a more personalized approach, could mean reducing unnecessary treatment and associated adverse events and complications (bladder scarring, performations, bladder crippling, urethral stricture ect), as well as costs and delays in adjuvant therapy.
- This competitive grant program seeks to support independent medical education activities that will increase awareness on the burden of unmet needs in patients with BCG-naive, HR-NMIBC, emerging data and appropriate patient selection and identification.
Funding Information
Individual projects requesting up to $50,000-$200,000 will be considered. A total of $500,000 will be available for funding multiple projects.
Grant Period
Maximum project length is 18-24 months.
Eligibility Criteria
- The following may apply: medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional organizations/medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.
- Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society).
- If the project involves multiple departments within an institution and/or between different institutions/ organizations / associations, all institutions must have a relevant role, and the requesting organization must have a key role in the project.
- The applicant must be the project/program lead or an authorized designee of such individual (e.g., project/program lead’s grant coordinator).
- The project/program lead must be an employee or contractor of the requesting organization.
- Requesting organization must be legally able to receive award funding directly from Pfizer Inc. Theystrongly recommend that applicants confirm this with their organization or institution prior to submitting an application. Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Pfizer Inc. may be subject to rescission.
- For projects offering continuing education credit, the requesting organization must be accredited.
For more information, visit Pfizer.
